Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

$ 9.50

4.8 (750) In stock

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates

Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)

COVID-19: A Collection of Articles, Collections

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques - ScienceDirect

Biomedicines, Free Full-Text

Frontiers T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets

Frontiers Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines

Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2

PDF) Beta variant COVID-19 protein booster vaccines elicit durable cross- neutralization against SARS-CoV-2 variants of concern in non-human primates

Biomedicines, Free Full-Text

Vaccines, Free Full-Text

Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants

Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

Omicron-specific booster may not be needed, U.S. monkey study finds